Form 4: CEL SCI Director Granted 4,000 Stock Options

CEL SCI Corp Director Bruno Baillavoine was granted 4,000 stock options with an exercise price of $8.20, vesting over three years.

Summary

• Bruno Jean-Marie Baillavoine, a Director of CEL SCI Corp (CVM), was granted 4,000 stock options on July 28, 2025.
• The options have an exercise price of $8.20 per share.
• The options vest in three equal annual installments, commencing one year after the grant date.
• The options expire on July 27, 2035.
• Following this transaction, Mr. Baillavoine beneficially owns a total of 28,017 derivative securities (options).

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of options aligns director interests with shareholders, which is generally viewed favorably, but it is a routine compensation event rather than a significant operational or financial announcement.

Positives

• Granting of stock options to a director aligns their interests with shareholders, incentivizing long-term performance.

Future Outlook

The vesting schedule indicates a future commitment and incentive structure for the director over the next three years from the grant date, aligning their long-term interests with the company's performance.

Industry Context

Stock option grants are a common form of executive and director compensation across various industries, particularly in biotechnology or growth-oriented companies like CEL SCI Corp, to align long-term interests and incentivize performance.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice in corporate governance across many industries, including biotechnology.
• The specific number of options (4,000) and exercise price ($8.20) would need to be compared against peer companies in the biotechnology sector (e.g., other clinical-stage biotechs with similar market caps or development pipelines) to assess if it's within typical ranges for director compensation. Without specific peer data, a detailed comparison is limited.

Corporate Governance

Related Party Transactions

• The grant of stock options to Director Bruno Baillavoine constitutes a related party transaction, which is a standard compensation practice.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholder value creation, potentially benefiting shareholders if the stock price increases.

Next Steps

• The options will vest in three equal annual installments, commencing one year after July 28, 2025.

Key Dates

Recommendation

This Form 4 filing reports a routine stock option grant to a director and does not contain information that would fundamentally alter the investment thesis for CEL SCI Corp. It is a standard compensation event designed to align interests, not an indicator of significant operational or financial performance changes. Therefore, a 'hold' recommendation is appropriate as it provides no new material information to warrant a change in investment stance.

Keywords

CEL SCI Corp, CVM, Stock Options, Director Compensation, Insider Transaction, Equity Grant, Executive Compensation, Form 4